U.S. flag An official website of the United States government

On Oct. 1, 2024, the FDA began implementing a reorganization impacting many parts of the agency. We are in the process of updating FDA.gov content to reflect these changes.

U.S. Food and Drug Administration
  1. Home
  2. About FDA
  3. Reports, Manuals, & Forms
  4. Reports
  5. Economic Impact Analyses of FDA Regulations
  6. Microbiology Devices; Classification of In Vitro Diagnostic Devices for Bacillus Species Detection (Final Rule) Regulatory Impact Analysis
  1. Economic Impact Analyses of FDA Regulations

Microbiology Devices; Classification of In Vitro Diagnostic Devices for Bacillus Species Detection (Final Rule) Regulatory Impact Analysis

The Food and Drug Administration is issuing a final rule to classify in vitro diagnostic devices for Bacillus species (spp.) detection into class II (special controls) and to continue to require a premarket notification (510(k)) to provide a reasonable assurance of safety and effectiveness of the device. FDA is also establishing special controls in a special controls guideline in addition to restricting use and distribution of the devices. An in vitro diagnostic device for Bacillus spp. detection is a prescription device used to detect and differentiate among Bacillus spp. and presumptively identify B. anthracis and other Bacillus spp. from cultured isolates or clinical specimens as an aid in the diagnosis of anthrax and other diseases caused by Bacillus spp.

Regulatory Impact Analysis

Microbiology Devices; Classification of In Vitro Diagnostic Device for Bacillus Species Detection (Final Rule) Regulatory Impact Analysis

Federal Register: 84 FR 12083, April 1, 2019

Docket: FDA-2011-N-0103

Back to Top